Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumors (NETs) while still effectively delivering treatment throughout the whole body. This hybrid approach safely delivered over three times more radiation directly to liver metastases, resulting in encouraging tumor responses among patients. This research was published online in the Journal of Nuclear Medicine.